At a glance
- Originator Fujisawa
- Class Neuroprotectants; Nootropics; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 29 Jun 2001 No-Development-Reported for Alzheimer's disease in Japan (Unknown route)
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 11 Jun 1996 Preclinical development for Alzheimer's disease in Japan (Unknown route)